SCHEMBL4792143

SCHEMBL4792143

CNC(Cc1ccc(Cl)cc1)C(=O)N1CC=C(c2cccc(-c3ccccc3)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.51
CNR1 P21554 1/20 0.49
NPC1 O15118 2/20 0.46
KMT2A Q03164 3/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
LMNA P02545 5/20 0.44
MAPT P10636 4/20 0.44
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 3/20 0.43
ALOX15 P16050 2/20 0.43
TSHR P16473 2/20 0.43
ALOX12 P18054 1/20 0.43
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PARP1 P09874 1/20 0.42
PPARG P37231 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771069 0.86 AKT1 (0.52) CCR1CNR1KMT2ALMNAMAPT
SCHEMBL4770788 0.86 AKT1 (0.52) CCR1CNR1KMT2ALMNAMAPT
SCHEMBL4793472 0.86 CCR1 (0.47) CCR1CNR1NPC1KMT2ACRHBP
SCHEMBL4775822 0.78 CNR1 (0.47) CCR1CNR1LMNAMAPTHTT
SCHEMBL4775641 0.77 CCR1 (0.56) CCR1KCNH2
SCHEMBL12603420 0.73 CCR1 (0.52) CCR1CNR1NPC1KMT2ACRHBP
SCHEMBL5959136 0.73 ALDH1A1 (0.57) CNR1NPC1KMT2ALMNAMAPT
Hydrochloric Acid SCHEMBL6177059 0.72 CCNT1 (0.49)
SCHEMBL2807104 0.71 ALDH1A1 (0.58) NPC1KMT2ALMNAMAPTALDH1A1
SCHEMBL4775621 0.70 MEN1 (0.61) CNR1NPC1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 CCR1 2053/4885CNR1 524/4885NPC1 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.